Celltex Therapeutics received FDA approval for a phase II clinical trial using mesenchymal stem cells (MSCs) as a prophylactic against COVID-19. Image courtesy of Celltex.

The company will initiate a phase I multicenter, randomized, double-blind, placebo-controlled study to evaluate ADMSCs. The study will enroll 200 patients who have never been infected with COVID-19. It will evaluate the overall safety of ADMSCs and demonstrate their efficacy as a prophylactic drug for those at high risk of becoming infected by the virus.

Sorrento moves forward with COVID-19 prophylactic drug
Sorrento has completed preclinical testing of STI-4398 (COVIDTRAP), reporting positive results on the protein's ability to neutralize and inhibit the...

Certara, DMTC study preventative use of chloroquine for COVID-19
Certara and DMTC have entered into a research collaboration to evaluate the preventative use of chloroquine in healthcare workers at risk of infection...

Experts discuss promising strategies for tackling SARS-CoV-2
What's the best strategy for developing treatments for the SARS-CoV-2 virus? The most promising approaches for a rapid response are antivirals and gene...